IRA: Second Round of 15 Medicare Drug Negotiations Selected

CMS announces 15 additional Part D drugs selected for the second round of Medicare price negotiation, including Ozempic/Wegovy (semaglutide), Keytruda (pembrolizumab), Biktarvy, Tremfya, and Vyvanse. The second round covers blockbuster drugs including the most expensive cancer and diabetes treatments on the market. Negotiated prices take effect January 1, 2027.